Related Experiment Video

Updated: Dec 16, 2025

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
09:45

An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells

Published on: May 21, 2019

8.8K

MicroRNA-92b acts as an oncogene by targeting PTEN/AKT in NSCLC

Jia-Hui Guo1, Hai-Yun Fang1, Jun-Mei Yang2

  • 1Department of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Cell Biochemistry and Function
|July 7, 2020
PubMed

Insights

MicroRNA-92b acts as an oncogene in non-small cell lung cancer (NSCLC). Upregulated miR-92b promotes NSCLC growth and spread by targeting PTEN and activating AKT signaling.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Regulation

Background:

  • MicroRNAs (miRNAs) are key regulators of cellular processes, acting as tumor suppressors or oncogenes.
  • Dysregulation of miRNA is implicated in the development of non-small cell lung cancer (NSCLC).

Purpose of the Study:

  • To investigate the role of miR-92b in NSCLC.
  • To elucidate the molecular mechanism by which miR-92b influences NSCLC progression.

Main Methods:

  • Quantitative real-time PCR to measure miR-92b expression in NSCLC tissues and cell lines.
  • In vitro and in vivo assays to assess the effects of miR-92b knockdown and overexpression on NSCLC cell proliferation and migration.
  • Western blotting and luciferase reporter assays to confirm the targeting of PTEN by miR-92b and its effect on the AKT pathway.

Main Results:

  • miR-92b was significantly upregulated in human NSCLC tissues and cell lines.
  • Knockdown of miR-92b inhibited NSCLC cell proliferation and migration in vitro and in vivo.
  • Overexpression of miR-92b promoted an aggressive phenotype in NSCLC cells.
  • miR-92b directly targets PTEN mRNA, leading to PTEN degradation and activation of the downstream AKT signaling pathway.

Conclusions:

  • miR-92b functions as an oncogene in NSCLC by targeting the PTEN/AKT pathway.
  • These findings highlight miR-92b as a potential therapeutic target for NSCLC treatment.
Keywords:
AktNSCLCOncogenesisPTENmicroRNA-92b

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.7K
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.9K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.5K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.7K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K